Skip to content
Research Article Open access CC BY 4.0

Investigation of FMS-Like Tyrosine Kinase 3 Mutation Frequency in Myelodysplastic Syndrome

Nesim Akin, Atakan Turgutkaya, Sare İlknur Yavaşoğlu, Esra Örenlili Yaylagül, Celal Ülger, Ali Zahit Bolaman, Irfan Yavasoglu

International Blood Research & Reviews · pp. 75–83 · Published 2 Nov 2021

10.9734/ibrr/2021/v13i130163

Abstract

Introduction: FMS-Like Tyrosine Kinase Class 3 (FLT3) mutations harbor poor prognosis, high relapse, and decreased overall survival in acute myeloblastic leukemia (AML). This mutation is also known to be demonstrated in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia and acute lymphoblastic leukemia. This study included 94 MDS-diagnosed patients and we tried to investigate FLT3 mutation frequency (as tyrosine kinase domain-TKD and internal tandem duplication-ITD). Materials and Methods: Polymerase chain reaction (PCR), restriction fragment length polymorphism, and agarose-gel electrophoresis methods were used to analyze the mutation. The blood samples were collected in K3-EDTA tubes, and total DNA was isolated using genomic DNA isolation kits (GeneMark, Cat No: DP023P). For the detection of FLT3-ITD mutation, PCR was performed to amplify a 330- base pair fragment of exons 11 and 12 of FLT3 using FAM (Carboxyfluorescein)-labeled ITD-11F and HEX (Hexachloro-Fluorescein )-labeled  ITD-12R primers in a thermal cycler (Eppendorf). Similarly, to detect D835 mutation, a 115- bp region of exon 17 of the FLT3 gene region was amplified using primers. Results: One patient was found FLT3-ITD positive (1.1%). The patient was 64-year-old and diagnosed with MDS-excess blast type 2 according to the World Health Organisation 2016 myeloid neoplasm classification. He transformed to AML within 19 months and subsequently died after 1 month. No patient with tyrosine kinase domain mutation was detected. Conclusion: FLT3 mutation is considered a significant parameter to define prognosis in AML. The routine workup of FLT3 screening and the potential of targeting FLT3 inhibition for high-risk MDS may be taken into consideration in the future.

Cytopenia FMS-like tyrosine kinase mutation myelodysplastic syndrome prognosis

References (17)

  1. 1 The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [DOI]
  2. 2 Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies [DOI]
  3. 3 Targeting FLT3 mutations in AML: review of current knowledge and evidence [DOI]
  4. 4 FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions [DOI]
  5. 5 Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay [DOI]
  6. 6 A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia [DOI]
  7. 7 FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia [DOI]
  8. 8 Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia [DOI]
  9. 9 Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia [DOI]
  10. 10 Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia [DOI]
  11. 11 Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia [DOI]
  12. 12 The Molecular Pathology of Myelodysplastic Syndrome [DOI]
  13. 13 Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib [DOI]
  14. 14 Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes [DOI]
  15. 15 The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population [DOI]
  16. 16 Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes [DOI]
  17. 17 EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter [DOI]

Cited by 2

Telomere shortening in middle-aged and elderly individuals with varying severities of obstructive sleep apnea

Yao-Pang Chung, Wei-Sheng Chung · Scientific Reports · 2025

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

40

Page views

0

PDF downloads

8

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.